Article: article from journal or magazin.
IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma.
Publication types: Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov'tPublication Status: ppublish
Mutations in isocitrate dehydrogenase 1 (IDH1) and isocitrate dehydrogenase 2 (IDH2) occur in most grade 2 and 3 gliomas, secondary glioblastomas, and a subset of acute myelogenous leukemias but have not been detected in other tumor types. The mutations occur at specific arginine residues and result in the acquisition of a novel enzymatic activity that converts 2-oxoglutarate to D-2-hydroxyglutarate. This study reports IDH1 and IDH2 genotyping results from a set of lymphomas, which included a large set of peripheral T-cell lymphomas. IDH2 mutations were identified in approximately 20% of angioimmunoblastic T-cell lymphomas (AITLs), but not in other peripheral T-cell lymphoma entities. These results were confirmed in an independent set of AITL patients, where the IDH2 mutation rate was approximately 45%. This is the second common genetic lesion identified in AITL after TET2 and extends the number of neoplastic diseases where IDH1 and IDH2 mutations may play a role.
Aged, Female, Gene Frequency, Genotype, Humans, Immunoblastic Lymphadenopathy/enzymology, Immunoblastic Lymphadenopathy/genetics, Isocitrate Dehydrogenase/genetics, Kaplan-Meier Estimate, Lymphoma, T-Cell/enzymology, Lymphoma, T-Cell/genetics, Lymphoma, T-Cell, Peripheral/enzymology, Lymphoma, T-Cell, Peripheral/genetics, Male, Mutation, Mutation Rate, Prognosis
Web of science
Last modification date